Leerink Partners Initiates Coverage On Sagimet Biosciences with Outperform Rating, Announces Price Target of $26
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Thomas Smith has initiated coverage on Sagimet Biosciences (NASDAQ:SGMT) with an Outperform rating and set a price target of $26.
March 25, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has initiated coverage on Sagimet Biosciences with an Outperform rating and a price target of $26.
The initiation of coverage by Leerink Partners with an Outperform rating and a significant price target suggests a positive outlook for Sagimet Biosciences. This endorsement from a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100